Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CyPep-1 intratumoral monotherapy and pembrolizumab combination in advanced solid cancers
NL-OMON54523Phase 1Completed
- Sponsor
- Cytovation
- Start
- Apr 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of cypep-1 and pembrolizumab in Non-hematologic malignancy, lymphoma and melanoma (4 arms), sponsored by Cytovation. Primary endpoints: Adverse events and Dose-limiting toxicities and recommended phase II dose. Started Apr 2020; status: completed.
02
Drugs
cypep-1pembrolizumab
03
Conditions
Non-hematologic malignancylymphomamelanoma
Beyond the preview
Go deeper on NL-OMON54523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54523.